1 Min Read
Sept 4 (Reuters) - Prescient Therapeutics Ltd
* U.S. FDA has lifted clinical hold on co’s phase 1b/2 clinical trial of PTX-200 in patients with refractory or relapsed acute myeloid leukemia Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.